Crohn's Disease (CD) Treatment Market Report 2026

Crohn's Disease (CD) Treatment Market Overview

• Crohn's Disease (CD) Treatment market size has reached to $12.32 billion in 2025 • Expected to grow to $16.01 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Increasing Prevalence Of Inflammatory Bowel Diseases Fuels Growth In The Crohn’S Disease Treatment Market • Market Trend: Innovative Diagnostic Technologies Enhance Non-Invasive Detection And Disease Monitoring In The Market • North America was the largest region in 2025.

What Is Covered Under Crohn's Disease (CD) Treatment Market?

Crohn's disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn's disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition. The main drug types of crohn's diseases treatment are antibiotics, amino salicylates, corticosteroids, immunomodulators, and other drug types. Antibiotics are medicines that fight bacterial infections in people and animals by killing the bacteria or making it hard for them to grow and multiply. The route of administration includes oral and injectable, which are distributed to through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

What Is The Crohn's Disease (CD) Treatment Market Growth Forecast?

The crohn's disease (cd) treatment market size is expected to see strong growth in the next few years. It will grow to $16.01 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in biologics development, growth of precision medicine, expanding patient awareness, improved diagnostic techniques, increased specialty gastroenterology care. Major trends in the forecast period include rising use of biologic therapies, expansion of targeted small molecule drugs, increased focus on long-term disease remission, growth of personalized treatment approaches, integration of combination therapy regimens.

What Is The Driver Of The Crohn's Disease (CD) Treatment Market?

The increasing prevalence of inflammatory bowel diseases is expected to propel the growth of the Crohn’s disease (CD) treatment market going forward. Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders primarily affecting the gastrointestinal (GI) tract. Crohn’s disease (CD) treatment offers relief from symptoms, reduces inflammation, promotes remission and enhances the overall quality of life for individuals suffering from chronic inflammatory bowel disease. For instance, in September 2023, the United States National Library of Medicine, a US-based medical library, estimated that in Canada, the incidence of inflammatory bowel diseases (IBD) was estimated at 30 per 100,000 person years in 2023, with projections indicating a steady increase of approximately 0.58% per year. As of 2023, the prevalence of IBD in Canada reached about 825 per 100,000, with forecasts suggesting that this could rise to 1.1% of the population by 2035. Therefore, the increasing prevalence of inflammatory bowel diseases drives the Crohn’s disease (CD) treatment market.

Key Players In The Global Crohn's Disease (CD) Treatment Market

Major companies operating in the crohn's disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann‑La Roche

Global Crohn's Disease (CD) Treatment Market Trends and Insights

Major companies operating in the Crohn’s disease (CD) treatment market are focusing on developing advanced technologies, such as non-invasive biomarker-based diagnostic platforms, to improve disease detection, enhance monitoring accuracy, and support personalized treatment decisions. Non-invasive diagnostic technologies in Crohn’s disease refer to tools that analyze biological samples without requiring invasive procedures, enabling earlier identification of inflammation, better tracking of disease activity, and improved patient experience. For instance, in March 2023, The IRR Chemistry Hub, a Scotland-based interdisciplinary research center, developed IBDSENSE, a fluorescence-based technology designed to enhance diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease. The platform measures the enzyme activity of Granzyme B (GzmB) in patient biosamples, offering a patient-friendly, non-invasive method to assess disease progression and inform therapeutic choices.

What Are Latest Mergers And Acquisitions In The Crohn's Disease (CD) Treatment Market?

In June 2023, Merck & Co. Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. With this acquisition, Merck & Co. aims to expand its product portfolio in immunological and inflammatory condition treatment drugs. Prometheus Biosciences is a US-based biotechnology company involved in developing inflammatory disease drugs and has expertise in Crohn’s disease and inflammatory bowel disease treatments.

What Defines the Crohn's Disease (CD) Treatment Market?

The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Crohn's Disease (CD) Treatment Market Report 2026?

The crohn's disease (cd) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the crohn's disease (cd) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.